Merck Sharp & Dohme: New Analysis of Pooled Clinical Data Shows ‘Januvia(R)’ (sitagliptin) from MSD Provided Significant Blood Sugar Lowering over Two Years

VIENNA--(BUSINESS WIRE) -- A post-hoc analysis, presented at the 45th Annual Meeting of the European Association for the Study of Diabetes (EASD), of data pooled from studies of 104 weeks in duration showed ‘Januvia®’ (sitagliptin), when taken alone or in combination with metformin, provided significant blood sugar lowering over two years.

MORE ON THIS TOPIC